Rapid Micro Biosystems, Inc.

As of June 30, 2026, Rapid Micro Biosystems, Inc. carries a market capitalization of 86.44M, placing it among publicly traded companies globally. Its enterprise value stands at 90.15M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rapid Micro Biosystems, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Rapid Micro Biosystems, Inc. has 49.97M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.25, and the price-to-book ratio stands at 4.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 90.15M versus a market cap of 86.44M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rapid Micro Biosystems, Inc. maintains a current ratio of 2.55, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 132.29, indicating elevated leverage, while an interest coverage ratio of -19.90 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Rapid Micro Biosystems, Inc. posted a negative return on equity (ROE) of -141.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -76.40, reflecting losses generated across the asset base. The company generates approximately 208,142.01 in revenue per employee across its workforce of 169.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.68 indicates how many times Rapid Micro Biosystems, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Rapid Micro Biosystems, Inc. recorded 75,000.00 in income tax expense. The company reported a pretax loss of -51.12M and -51.20M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 27, 2026, Rapid Micro Biosystems, Inc.'s stock has declined approximately 73.31% over the past 52 weeks. The 50-day moving average sits at 1.15, while the 200-day moving average is 2.28.

Over the twelve months ended June 30, 2026, Rapid Micro Biosystems, Inc. generated 35.18M in revenue and converted that into -51.20M in net income, yielding earnings per share of -1.12. EBITDA reached -46.78M, while operating income came in at -49.76M.

As of June 30, 2026, Rapid Micro Biosystems, Inc. holds 19.77M in cash and equivalents against 23.48M in total debt, resulting in a net debt position of 4.45M. Total book value stands at 17.75M, with working capital of 28.11M providing operational flexibility.

Rapid Micro Biosystems, Inc. produced -40.06M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -336,000.00 in capital expenditures, free cash flow totaled -40.39M - equivalent to -0.88 per share.

Over the twelve months ended June 30, 2026, Rapid Micro Biosystems, Inc. posted a gross margin of 5.55, reflecting its pricing power and cost economics. The operating margin of -141.45 and net profit margin of -145.55 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -50.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -33.88, meaning Rapid Micro Biosystems, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Rapid Micro Biosystems, Inc. has an Altman Z-Score of -13.52, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.